February 11, 2019

EIP Pharma to Present at BIO CEO Investor Conference

CAMBRIDGE, Mass., February 11, 2019 — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that company management will present at the BIO CEO Investor Conference. The presentation will take place at 10:00 a.m. ET on February 12, 2019 in New York City.

A live audio webcast of the event will be available on the Contact & News section of EIP’s website at A replay of the webcast will be archived on EIP’s website for 90 days following the event.

About EIP Pharma
 EIP Pharma, Inc. is a private, Cambridge, MA-based company advancing CNS-focused therapeutics for improved patient benefit. EIP’s lead program is neflamapimod, a brainpenetrant oral small molecule that inhibits the enzyme p38 alpha, an intracellular kinase implicated in the development of synaptic dysfunction (SD) in Alzheimer’s disease. EIP Pharma recently completed enrollment into the REVERSE-SD clinical study, a phase 2b proof-of-concept clinical study of neflamapimod in early Alzheimer’s disease. The results of REVERSE-SD will be available in the fourth quarter of 2019.

For more information, please visit

For further information, please contact:

Kevin Sarney

John Alam


Are you a patient, caregiver, clinician or professional and want to learn more about CERVOMED’s approach? Please contact us.

Contact Us